EyeBio Raise $65M in Series A Funding for the Development of a New Generation of Eye Disease Therapies.
EyeBio have announced their successful $65M Series A funding to develop new generation of eye disease therapies. Their aim is to ‘protect, restore and improve vision’ of patients, they will use this funding to assemble and develop a ‘diversified pipeline of product candidates’ that combines scientific targets with innovative translational approaches.
“Advances in research are revealing new opportunities to translate science into solutions that serve patients with eye diseases who have urgent and unaddressed medical needs” Dr David Guyer, CEO EyeBio.
The Series A funding will bring together an international team of executives and investors with a track record for developing #ophthalmology therapies.
Follow Vision Executives to stay up to date with the latest #eyecare news and vacancies.
James Pickering is our Managing Director and an eye care recruitment expert who has developed an extensive client base and candidate network. He regularly writes articles about industry developments and has received numerous recommendations from industry leaders. You can also connect with James on LinkedIn to stay up to date on the latest eye care news.